Doctors and patients should rigorously evaluate diagnosis and treatment compliance before turning to biologics, two ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

Biologics, including medications like mepolizumab and dupilumab, are widely prescribed for patients with severe asthma and ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Recommended management of asthma, including appropriate diagnostic steps and use of fractional exhaled nitric oxide (FeNO) in ...

A group of South West-based researchers have shown that early improvements in asthma symptoms can help predict how effective ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Allergy and Clinical Immunology Division is marking World Allergy Week 2025 by highlighting the range of specialised services ...